Literature DB >> 2845711

Monoamine oxidase inhibitor withdrawal phenomena: symptoms and pathophysiology.

S C Dilsaver1.   

Abstract

The author reviews the literature reporting the untoward effects of withdrawing monoamine oxidase inhibitors (MAOIs). The withdrawal of these agents can result in severe anxiety, agitation, pressured speech, sleeplessness or drowsiness, hallucinations, delirium and paranoid psychosis. MAOI withdrawal phenomena resemble the symptoms produced by the discontinuation of chronically administered psychostimulants. The capacity of MAOI to exert amphetamine-like effects presynaptically, and the propensity of somatic treatments for depression to subsensitize presynaptic receptors regulating the release of catecholamines, can provide a basis for the development of psychotic syndromes upon the withdrawal of MAOIs. Evidence for this hypothesis is reviewed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2845711     DOI: 10.1111/j.1600-0447.1988.tb06293.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  5 in total

Review 1.  Delirium: an important (but often unrecognized) clinical syndrome.

Authors:  Terry Rabinowitz
Journal:  Curr Psychiatry Rep       Date:  2002-06       Impact factor: 5.285

2.  Delirium, thrombocytopenia, insomnia, and mild liver damage associated with MAOI withdrawal.

Authors:  Alfredo Bellon; John H Coverdale
Journal:  Eur J Clin Pharmacol       Date:  2009-12       Impact factor: 2.953

3.  Tranylcypromine withdrawal phenomena.

Authors:  M T Halle; S C Dilsaver
Journal:  J Psychiatry Neurosci       Date:  1993-01       Impact factor: 6.186

Review 4.  Metabolism of monoamine oxidase inhibitors.

Authors:  G B Baker; L J Urichuk; K F McKenna; S H Kennedy
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

5.  Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively.

Authors:  Samuel R Chamberlain; David S Baldwin
Journal:  CNS Drugs       Date:  2021-07-09       Impact factor: 5.749

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.